Wall Street Transcript Interview with Terrance H. Gregg, the CEO of Dexcom, Inc. (DXCM)

Wall Street Transcript

67 WALL STREET, New York - August 1, 2014 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Affordable Care Act - Aging U.S. Population - Medical Technology Innovation - Medical Equipment Growth Opportunities - Efficient Patient Treatment - Bifurcation in Medical Devices

Companies include: DexCom, Inc. (DXCM) and many more.

In the following excerpt from the Medical Devices Report, the CEO of Dexcom, Inc. (DXCM) discusses company strategy and the outlook for this vital industry:

TWST: Who are your competitors, and how are you different from them?

Mr. Gregg: That is interesting. So I'm always asked the question about the competitors, and I always say, "Well, the fingerstick meters are our competitors," and the reason I say that is because our long-term goal had clearly been to replace fingersticks. And most recently, at the American Diabetes Association Meeting in San Francisco last week, we had a poster session, which showed the accuracy of the gen four with an advanced algorithm to have a 9% relative difference to blood glucose. And so we've crossed that critical threshold of what we had always considered the barrier to get to a replacement claim. So now we obviously have to engage the FDA in additional discussions about what the appropriate clinical trial would look like in order for us to achieve that claim.

Going from the investment community, I think they always identify Medtronic Diabetes as our current competitor because they are the only other company today that has an approved product that is a CGM product - although that product is integrated with their pump system. They don't sell a product that is similar to ours for unique ambulatory use at this point in time. And how we differentiate ourselves, even from their system is: Number one, we're 50% more accurate even with today's technology, and we have not incorporated this new algorithm. We are more durable, and we are easier to use because we are in a completely different segment in terms of ambulatory use, given that we are not connected to a pump as a requirement.

TWST: In what markets do you sell geographically, and how do you expect that to change? I am assuming geography mix is dependent on regulatory approval.

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)